Mostrar el registro sencillo del ítem

dc.contributor.authorTrojan A.
dc.contributor.authorLone Y.-C.
dc.contributor.authorBriceno I.
dc.contributor.authorTrojan J.
dc.date.accessioned2024-11-12T13:43:05Z
dc.date.available2024-11-12T13:43:05Z
dc.date.issued2024
dc.identifier.issn9298673
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85185708388&doi=10.2174%2f0109298673237968231106095141&partnerID=40&md5=b4b108fc2f61f00d93fce204e96dce3a
dc.identifier.urihttp://hdl.handle.net/10818/62779
dc.description.abstractObjective: Vaccines for the deadliest brain tumor-glioblastoma (GBM)-are generally based on targeting growth factors or their receptors, often using antibodies. The vaccines described in the review were prepared to suppress the principal cancer growth factor-IGF-I, using anti-gene approaches either of antisense (AS) or of triple helix (TH) type. Our objective was to increase the median survival of patients treated with AS and TH cell vaccines. Methodology: The cells were transfected in vitro by both constructed IGF-I AS and IGF-I TH expression episomal vectors; part of these cells was co-cultured with plant phytochemicals, modulating IGF-I expression. Both AS and TH approaches completely suppressed IGF-I expression and induced MHC-1/B7 immunogenicity related to the IGF-I receptor signal. Results: This immunogenicity proved to be stronger in IGF-I TH than in IGF-I AS-prepared cell vaccines, especially in TH/phytochemical cells. The AS and TH vaccines generated an important TCD8+ and TCD8+CD11b-immune response in treated GBM patients and increased the median survival of patients up to 17-18 months, particularly using TH vaccines; in some cases, 2-and 3-year survival was reported. These clinical results were compared with those obtained in therapies targeting other growth factors. Conclusion: The anti-gene IGF-I vaccines continue to be applied in current GBM personalized medicine. Technical improvements in the preparation of AS and TH vaccines to increase MHC-1 and B7 immunogenicity have, in parallel, allowed to increase in the median survival of patients. © 2024 Bentham Science Publishers.en
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherCurrent Medicinal Chemistryes_CO
dc.relation.ispartofseriesCurrent Medicinal Chemistry Vol. 31 N° 15
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherAnti-Gene Technologyen
dc.subject.otherCancer gene therapyen
dc.subject.otherGlioblastomaen
dc.subject.otherIgf-Ien
dc.subject.otherImmuno-Gene Vaccineen
dc.subject.otherSignal transductionen
dc.titleAnti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastomaen
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.2174/0109298673237968231106095141


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International